Entera Bio Ltd. (NASDAQ:ENTX) Sees Large Increase in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 332,658 shares, a growth of 107.8% from the June 15th total of 160,118 shares. Based on an average daily volume of 5,613,473 shares, the short-interest ratio is currently 0.1 days. Approximately 0.8% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ENTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Trading of Entera Bio

Hedge funds and other institutional investors have recently modified their holdings of the company. Superstring Capital Management LP purchased a new position in Entera Bio in the fourth quarter valued at about $33,000. Citadel Advisors LLC lifted its holdings in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the last quarter. HighTower Advisors LLC lifted its holdings in shares of Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Entera Bio by 142.6% in the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after buying an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Entera Bio by 22.2% in the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after buying an additional 19,601 shares in the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Stock Performance

Shares of ENTX stock traded up $0.22 during trading on Thursday, hitting $2.00. 570,194 shares of the company were exchanged, compared to its average volume of 593,509. The firm has a market capitalization of $98.58 million, a price-to-earnings ratio of -7.41 and a beta of 1.43. The business’s 50-day simple moving average is $1.38 and its 200 day simple moving average is $1.38. Entera Bio has a twelve month low of $0.91 and a twelve month high of $3.22.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. On average, equities analysts forecast that Entera Bio will post -0.34 earnings per share for the current fiscal year.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.